IL136377A0 - Glucagon-like peptide-1 crystals - Google Patents

Glucagon-like peptide-1 crystals

Info

Publication number
IL136377A0
IL136377A0 IL13637798A IL13637798A IL136377A0 IL 136377 A0 IL136377 A0 IL 136377A0 IL 13637798 A IL13637798 A IL 13637798A IL 13637798 A IL13637798 A IL 13637798A IL 136377 A0 IL136377 A0 IL 136377A0
Authority
IL
Israel
Prior art keywords
glucagon
crystals
peptide
Prior art date
Application number
IL13637798A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL136377A0 publication Critical patent/IL136377A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13637798A 1997-12-16 1998-12-14 Glucagon-like peptide-1 crystals IL136377A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6972897P 1997-12-16 1997-12-16
PCT/US1998/026480 WO1999030731A1 (fr) 1997-12-16 1998-12-14 Cristaux de peptide 1 du type glucagon

Publications (1)

Publication Number Publication Date
IL136377A0 true IL136377A0 (en) 2001-06-14

Family

ID=22090845

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13637798A IL136377A0 (en) 1997-12-16 1998-12-14 Glucagon-like peptide-1 crystals

Country Status (24)

Country Link
US (3) US6380357B2 (fr)
EP (1) EP0926159A3 (fr)
JP (1) JP2002508332A (fr)
KR (1) KR20010033146A (fr)
CN (1) CN1281369A (fr)
AR (1) AR019806A1 (fr)
AU (1) AU1821899A (fr)
BR (1) BR9813658A (fr)
CA (1) CA2315243A1 (fr)
CO (1) CO5040043A1 (fr)
CZ (1) CZ20002104A3 (fr)
EA (1) EA200000652A1 (fr)
HR (1) HRP20000409A2 (fr)
HU (1) HUP0100046A2 (fr)
ID (1) ID25534A (fr)
IL (1) IL136377A0 (fr)
NO (1) NO20003081L (fr)
NZ (1) NZ505182A (fr)
PE (1) PE20000059A1 (fr)
PL (1) PL341210A1 (fr)
SV (1) SV1998000147A (fr)
TR (1) TR200001726T2 (fr)
WO (1) WO1999030731A1 (fr)
ZA (1) ZA9811466B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ES2526707T3 (es) 1999-06-29 2015-01-14 Mannkind Corporation Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7598222B2 (en) 2000-01-27 2009-10-06 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 compounds
WO2001057084A1 (fr) * 2000-01-31 2001-08-09 Novo Nordisk A/S Cristallisation d'un analogue de glp-1
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
CA2380423A1 (fr) * 2000-05-17 2001-11-22 Bionebraska, Inc. Preparations pharmaceutiques peptidiques
DK1294757T3 (da) * 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US20030119734A1 (en) * 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
MXPA04001525A (es) * 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
EP1463751B1 (fr) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Proteines hybrides d'albumine
KR20040085205A (ko) * 2002-02-20 2004-10-07 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 분자의 투여 방법
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
RU2357750C2 (ru) 2002-12-31 2009-06-10 Элтус Фармасьютикалз Инк. Кристаллы человеческого гормона роста и способы их получения
CA2512001A1 (fr) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes de cristaux proteiques et de polymeres ioniques
JP4887139B2 (ja) * 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
WO2004105781A2 (fr) * 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions pharmaceutiques peptidiques stabilisees
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) * 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) * 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) * 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP5518282B2 (ja) * 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7790734B2 (en) * 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
HUE038395T2 (hu) * 2003-11-20 2018-10-29 Novo Nordisk As Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
US7521527B2 (en) * 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134231B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EP1753730A1 (fr) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
WO2006023849A2 (fr) 2004-08-20 2006-03-02 Mannkind Corporation Catalyse de la synthese de dicetopiperazine
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
WO2006024631A2 (fr) * 2004-08-31 2006-03-09 Novo Nordisk A/S Utilisation de tris(hydroxymethyl)aminomethane pour la stabilisation de peptides, polypeptides et proteines
AU2005303777B2 (en) 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
EP2805953B1 (fr) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Inhibiteurs de peptidase dipeptidyl
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US20070004616A1 (en) * 2005-06-30 2007-01-04 Roland Cherif-Cheikh GLP-1 pharmaceutical compositions
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
ES2559677T3 (es) 2005-09-14 2016-02-15 Mannkind Corporation Método de formulación de fármacos basado en aumentar la afinidad de los principios activos por superficies de partículas microcristalinas
CA2622472C (fr) * 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
ES2445180T5 (es) * 2005-09-14 2022-02-01 Takeda Pharmaceuticals Co Administración de inhibidores de dipeptidil peptidasa
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
CN102675221A (zh) * 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
WO2007102946A2 (fr) * 2006-01-23 2007-09-13 Amgen Inc. Polypeptides cristallins
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2007112368A1 (fr) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Préparation de dichlorhydrate de (r)-3-aminopipéridine
MX2008013168A (es) * 2006-04-13 2008-10-27 Sod Conseils Rech Applic Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
CA2663279C (fr) * 2006-09-13 2016-05-17 Takeda Pharmaceutical Company Limited Utilisation du 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,-4-dioxo-3,4-dihydro-2h-pyridimin-1-ylmethyl-4-fluoro-benzonitrile pour le traitement du diabete, du cancer, des maladies auto-immunes et de l'infection au vih
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
BRPI0818874A2 (pt) * 2007-10-24 2015-05-05 Mannkind Corp Liberação de agentes ativos
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
DK2211842T3 (en) * 2007-10-24 2015-09-21 Mannkind Corp An inhalable dry powder formulation COMPREHENSIVE GLP-1 FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DIABETES BY pulmonary delivery
MY176697A (en) 2008-06-13 2020-08-19 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2609954T3 (da) 2008-06-20 2022-02-14 Mannkind Corp Interaktivt apparat til realtidsafbildning af inhalationspræstationer
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5918539B2 (ja) 2009-01-08 2016-05-18 マンカインド コーポレイション Ｇｌｐ−１を用いる高血糖症の治療方法
EP2216042A1 (fr) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. Compositions pharmaceutiques analogues au GLP-1
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CA2764505C (fr) 2009-06-12 2018-09-25 Mannkind Corporation Microparticules de dicetopiperazine avec des surfaces specifiques definies
EP2482840A4 (fr) * 2009-08-07 2013-06-26 Mannkind Corp Composition glp-1 val (8) et procédé de traitement de la dyspepsie fonctionnelle et/ou du syndrome du côlon irritable
CA2778698A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et methode de simulation d'efforts d'inhalation
WO2011140176A1 (fr) 2010-05-04 2011-11-10 Glaxosmithkline Llc Méthodes de traitement ou de prévention de troubles cardiovasculaires, et de fourniture d'une protection cardiovasculaire
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
EP2600887A4 (fr) 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc Agonistes microcristallins des récepteurs y
WO2012135765A2 (fr) 2011-04-01 2012-10-04 Mannkind Corporation Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
WO2013063160A1 (fr) 2011-10-24 2013-05-02 Mannkind Corporation Procédés et compositions pour traiter la douleur
MY176411A (en) 2012-07-12 2020-08-06 Mannkind Corp Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN104107422A (zh) * 2013-04-16 2014-10-22 石药集团中奇制药技术（石家庄）有限公司 重组胰高血糖素样肽-1受体激动剂的注射用药物组合物
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
BR112016016321A2 (pt) * 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA3082033A1 (fr) 2017-08-24 2019-02-28 Novo Nordisk A\S Compositions de glp-1 et leurs utilisations
CN108042794B (zh) * 2018-01-05 2022-01-25 北京博康健基因科技有限公司 重组促胰岛素分泌素的稳定制剂及其制备方法
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
EP0646128A1 (fr) 1992-06-15 1995-04-05 Scios Inc. Derives d'insulinotropine et de peptide analogue au glucagon
SE9302278D0 (sv) * 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
WO1995005848A1 (fr) 1993-08-24 1995-03-02 Novo Nordisk A/S Peptide-1 du type glucagon a action prolongee
CA2137206A1 (fr) * 1993-12-09 1995-06-10 John A. Galloway Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (fr) 1996-11-12 2005-02-23 Novo Nordisk A/S Utilisation de peptides glp-1
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals

Also Published As

Publication number Publication date
EP0926159A3 (fr) 2003-11-26
US6555521B2 (en) 2003-04-29
US20030045464A1 (en) 2003-03-06
NO20003081D0 (no) 2000-06-15
PL341210A1 (en) 2001-03-26
PE20000059A1 (es) 2000-02-09
CZ20002104A3 (cs) 2001-08-15
HRP20000409A2 (en) 2000-10-31
CO5040043A1 (es) 2001-05-29
JP2002508332A (ja) 2002-03-19
ID25534A (id) 2000-10-12
NZ505182A (en) 2002-05-31
BR9813658A (pt) 2000-10-10
KR20010033146A (ko) 2001-04-25
CA2315243A1 (fr) 1999-06-24
WO1999030731A1 (fr) 1999-06-24
HUP0100046A2 (hu) 2001-05-28
AU1821899A (en) 1999-07-05
US20010014666A1 (en) 2001-08-16
AR019806A1 (es) 2002-03-20
NO20003081L (no) 2000-08-08
EA200000652A1 (ru) 2000-12-25
US6380357B2 (en) 2002-04-30
CN1281369A (zh) 2001-01-24
USRE41133E1 (en) 2010-02-16
ZA9811466B (en) 2000-06-14
SV1998000147A (es) 1999-08-18
EP0926159A2 (fr) 1999-06-30
TR200001726T2 (tr) 2000-10-23

Similar Documents

Publication Publication Date Title
IL136377A0 (en) Glucagon-like peptide-1 crystals
HUP9903714A3 (en) Glp-1 derivatives
DE69803272D1 (en) Hemmstoffe der stickstoffmonoxid-synthase
EP0927917A4 (fr) Montre-bracelet
HK1010473A1 (en) Watchband
TW376222U (en) Ballast
AU6586298A (en) Glucagon-like peptide-1 analogs
HK1014384A1 (en) Watch with exchangeable elements
EP0965321A4 (fr) Composition a usage externe
GB9808537D0 (en) Lockset
EP0795562A4 (fr) Nouvelle oxyntomoduline
SI1140148T1 (sl) Stabilna formulacija raztopine glukagonu podobnega peptida-1
EP0928983A4 (fr) Montre
IL115062A0 (en) Spirostanyl glycosidal crystals
ZA988492B (en) Substituted tetrahydro-naphthalenes and analogous compounds
AU134216S (en) Timepiece
GB2327232B (en) Screens
GB9708262D0 (en) Degaussing circuitry
FI104298B1 (fi) Resonaattorirakenne
HU1000133D0 (en) Glp-1 derivatives
EP1011665A4 (fr) Agents heterocycliques
CA81817S (en) Watch
CA81892S (en) Watch
GB9700346D0 (en) Polarizers
TW317944U (en) Timepiece structure improvement